Sethi R, Mohan L, Vishwakarma P, Singh A, Sharma S, Bhandari M, Shukla A, Sharma A, Chaudhary G, Pradhan A, Chandra S, Narain VS, Dwivedi SK. Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction. World J Cardiol 2023; 15(1): 23-32 [PMID: 36714366 DOI: 10.4330/wjc.v15.i1.23]
Corresponding Author of This Article
Akshyaya Pradhan, MD, Professor, Department of Cardiology, King George's Medical University, Shah Mina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. akshyaya33@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Rishi Sethi, Lalit Mohan, Pravesh Vishwakarma, Abhishek Singh, Swati Sharma, Monika Bhandari, Ayush Shukla, Akhil Sharma, Gaurav Chaudhary, Akshyaya Pradhan, Sharad Chandra, Varun Shankar Narain, Sudhanshu Kumar Dwivedi, Department of Cardiology, King George's Medical University, Lucknow 226003, Uttar Pradesh, India
Author contributions: Sethi R and Mohan L conceived the project; Pradhan A, Vishwakarma P, Singh A, and Mohan L were involved in data collection; Shukla A, Bhandari M, Sharma S, and Chaudhary G analyzed the data; Pradhan A and Mohan L performed the literature search; Pradhan A and Sethi R drafted the manuscript; Narain VS, Dwivedi SK, and Chandra S critically reviewed the manuscript; Sethi R, Mohan L and Pradhan A prepared the final manuscript; Sethi R and Pradhan A submitted the initial version; Sethi R, Pradhan A, and Vishwakarma P revised the manuscript; Pradhan A and Vishwakarma P prepared the rebuttal; Pradhan A submitted the revised version.
Institutional review board statement: The study protocol was approved by the local Institutional Review Board and was performed in accordance with Declaration of Helsinki.
Informed consent statement: Written informed consent was received from patient or from patient designees before enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Data is available with authors and can be made available on request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Akshyaya Pradhan, MD, Professor, Department of Cardiology, King George's Medical University, Shah Mina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. akshyaya33@gmail.com
Received: July 18, 2022 Peer-review started: July 18, 2022 First decision: September 26, 2022 Revised: November 14, 2022 Accepted: December 13, 2022 Article in press: December 13, 2022 Published online: January 26, 2023 Processing time: 177 Days and 21.6 Hours
Core Tip
Core Tip: Pharmacoinvasive strategy with percutaneous coronary intervention (PCI) within 3 to 24 h after successful thrombolysis has been proven to be a viable alternative to primary PCI. In resource poor countries, patients often present to the interventionist beyond 24 h of thrombolysis due to logistic reasons. The results of this study demonstrate that the clinical outcomes of delayed pharmacoinvasive therapy (24-72 h of initiation of thrombolysis) are comparable to those of routine pharmacoinvasive (3-24 h of initiation of thrombolysis) in patients with acute ST-elevation myocardial infarction (STEMI). Hence, in critically diseased acute STEMI patients who have been timey thrombolysed, delayed PCI (24-72 h following thrombolysis) appears a reasonable strategy.
